Table 1.
Sepsis severity and outcomes of patients included in the discovery and validation cohorts. The mean value ± standard error is presented for numerical variables (total observations in brackets). Categorical variables are presented as % positive observations (relative to total observations). ER = value in the Emergency Room at first clinical presentation.
| Parameter | Demographic and Clinical Data |
|
|---|---|---|
| ER Patients (N = 182 in Discovery group; 84 in Validation cohort) | ICU Patients (N = 82) | |
| Age | 56 ± 1·3 (266) | 61·7 ± 1·7 (82) |
| Sex, Female | 45·5% (121/266) | 30·5% (25/82) |
| Location(s) | Endotype Discovery: Groningen, the Netherlands (39%); Neiva, Colombia (25%); Vancouver, Canada (4%); Endotype Validation: Sydney, Australia (32%) | Toronto, Canada (100%) |
| Duration of illness before ER/ICU arrival | 6·1 ± 0·87 (266) | 6·1 ± 0·85 (62) |
| ER qSOFA | 1·0 ± 0·05 (266) | Not applicable |
| ER/ICU 24H SOFA Score | 2·0 ± 0·12 (266) | 7·2 ± 0·55 (79) |
| Hospital/ICU stay (days) | 7·5 ± 0·54 (266) | 12·0 ± 1·0 (82) |
| Blood Culture Result | 19·2% (50/260) | 12·2% (10/82) |
| ICU Admission | 10·2% (27/266) | 98% (80/82)* |
| Mortality (In hospital) | 12·1% (32/265) | 24·4% (20/82) |
| SARS-CoV-2 PCR Positive | None | 32·9% (27/82)# |
⁎
2 patients collected from ward
#
Based on PCR for SARS-CoV-2 RNA of nasopharyngeal and/or endotracheal tube aspirates. All patients had evident early sepsis.